The Distinct Biological Implications of Asxl1 Mutation and Its Roles In

Total Page:16

File Type:pdf, Size:1020Kb

The Distinct Biological Implications of Asxl1 Mutation and Its Roles In Hsu et al. Journal of Hematology & Oncology (2017) 10:139 DOI 10.1186/s13045-017-0508-x RESEARCH Open Access The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model Yueh-Chwen Hsu1, Yu-Chiao Chiu2, Chien-Chin Lin1,3, Yuan-Yeh Kuo4, Hsin-An Hou5, Yi-Shiuan Tzeng4, Chein-Jun Kao3, Po-Han Chuang3, Mei-Hsuan Tseng5, Tzu-Hung Hsiao2, Wen-Chien Chou1,3,5* and Hwei-Fang Tien5* Abstract Background: Additional sex combs-like 1 (ASXL1) is frequently mutated in myeloid malignancies. Recent studies showed that hematopoietic-specific deletion of Asxl1 or overexpression of mutant ASXL1 resulted in myelodysplasia- like disease in mice. However, actual effects of a “physiological” dose of mutant ASXL1 remain unexplored. Methods: We established a knock-in mouse model bearing the most frequent Asxl1 mutation and studied its pathophysiological effects on mouse hematopoietic system. Results: Heterozygotes (Asxl1tm/+) marrow cells had higher in vitro proliferation capacities as shown by more colonies in cobblestone-area forming assays and by serial re-plating assays. On the other hand, donor hematopoietic cells from Asxl1tm/+ mice declined faster in recipients during transplantation assays, suggesting compromised long-term in vivo repopulation abilities. There were no obvious blood diseases in mutant mice throughout their life-span, indicating Asxl1 mutation alone was not sufficient for leukemogenesis. However, this mutation facilitated engraftment of bone marrow cell overexpressing MN1. Analyses of global gene expression profiles of ASXL1-mutated versus wild-type human leukemia cells as well as heterozygote versus wild-type mouse marrow precursor cells, with or without MN1 overexpression, highlighted the association of in vivo Asxl1 mutation to the expression of hypoxia, multipotent progenitors, hematopoietic stem cells, KRAS, and MEK gene sets. ChIP-Seq analysis revealed global patterns of Asxl1 mutation-modulated H3K27 tri-methylation in hematopoietic precursors. Conclusions: We proposed the first Asxl1 mutation knock-in mouse model and showed mutated Asxl1 lowered the threshold of MN1-driven engraftment and exhibited distinct biological functions on physiological and malignant hematopoiesis, although it was insufficient to lead to blood malignancies. Keywords: Asxl1, MN1, Hematopoietic stem cell, Engraftment Background developmental abnormalities [5]. ASXL1 binds a deubi- Additional sex combs-like 1 (ASXL1) is the human quitinase BAP1 to form a critical complex for H2A K119 homolog of Drosophila additional sex combs (Asx) [1], deubiquitination through the catalysis of polycomb frequently mutated in acute myeloid leukemia (AML) repressive complex 1 [6, 7]. The deubiquitination activity and other myeloid malignancies [2–4]. Germline hetero- is enhanced when BAP1 is complexed with truncated zygous nonsense mutation of ASXL1 results in Bohring- form of ASXL1 [8]. BAP1 deletion produces phenotypes Opitz syndrome, a congenital disease with multi-system mimicking human chronic myelomonocytic leukemia in mice [9]. Thus, it is likely that ASXL1-BAP1 axis is * Correspondence: [email protected]; [email protected] important to prevent leukemogenesis [9]. 1Graduate Institute of Clinical Medicine, National Taiwan University, Taipei, Taiwan We previously analyzed the clinical implications of 5Division of Hematology, Department of Internal Medicine, National Taiwan ASXL1 mutation in a large cohort of patients and found University Hospital, No. 7, Chung-Shan S Rd, Taipei 10002, Taiwan that this mutation occurred in 10.8% (54/501) of de Full list of author information is available at the end of the article © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Hsu et al. Journal of Hematology & Oncology (2017) 10:139 Page 2 of 15 novo AML patients and predicted a shorter survival marrow hematopoietic cells could lead to MDS-like dis- [10]. Several studies also showed that ASXL1 mutation ease [19], our mice bearing a “physiological dose” of mu- was a poor prognostic factor in myeloid malignancies tant Asxl1 did not show obvious trend of developing [10–14]. blood diseases throughout their life span. However, with Since the discovery of ASXL1 mutation in myeloid overexpression of MN1, mutant Asxl1 hematopoietic malignancies in 2009 [15], many studies about its patho- stem cells and progenitors (HSPCs) were more likely to physiology have been reported. However, controversies engraft in recipient mice than wild-type HSPCs, suggest- exist among these reports. For example, in vivo deletion ing that Asxl1 mutation could lower the threshold of of Asxl1 was shown to result in subtle phenotypes engraftment driven by MN1 overexpression. Global including defects in the frequencies of myeloid and expression profiling in mutant versus wild-type Asxl1 lymphoid cells in blood, marrow or other hematopoietic mouse cells as well as in ASXL1-mutated versus wild- organs in mice but not myelodysplastic syndrome type human AML cells, with or without concurrent (MDS) or leukemia [16]. However, in other studies, MN1 overexpression, disclosed pathophysiological path- knockout of Asxl1 led to systemic developmental defects ways involved in Asxl1 mutation. ChIP-Seq experiments including MDS-like presentation, with alteration of the showed global Asxl1 mutation-modulated H3K27me3 self-renewal and repopulation capacities of the mutant patterns in HSPCs. hematopoietic stem/progenitor cells and global reduc- tion of H3K27 tri-methylation (H3K27me3) [17, 18]. Methods The pathophysiological effect of ASXL1 truncation Generation of Asxl1 mutation knock-in mice mutations in human myeloid malignancies is another The cognate mouse mutation is predicted to be matter of debate. For example, it was suggested that c.1925dupG; p.G643WfsX12, encoding 654 amino acids ASXL1 mutation was a loss-of-function mutation mimicking the most common form of human mutant because of failure in detecting mutant protein in human ASXL1 protein, compared to 1514 residues in wild-type leukemia cells [14]. However, the findings that overex- Asxl1 protein. Potential chimeras were crossed with pression of truncating mutation in hematopoietic cells of wild-type C57BL/6 mice to facilitate the confirmation of mice displayed human MDS features with de-repression germ-line transmission, their offspring who harbored of Hoxa9 in another study [19] and detectability of trun- Asxl1 mutation were backcrossed with C57BL/6 to gen- cating proteins in human cell lines bearing ASXL1 trun- erate inbred strains then maintained at C57BL/6 back- cating mutations argued for gain-of-function or ground. Heterozygous mice were mated with wild-type dominant negative effects of ASXL1 mutations [19, 20]. mice to get heterozygous mice and littermate control These controversies are likely due to different methods mice. Heterozygous mice were mated with each other to of genetic engineering of the animals or forced overex- get homozygous mice. Mice between 2- to 6-month age pression of the mutation. Overall, the pathophysiological were used for experiment except those were assigned to alterations in human acute myeloid leukemia (AML) long-term observation cohort. All animals were housed cells bearing ASXL1 mutations have not been explored in specific pathogen-free animal facility and all proce- systematically. dures were approved by IACUC of the National Taiwan To overcome these problems, we generated and ana- University College of Medicine. lyzed a mouse model bearing human-like Asxl1 muta- tion followed by extensive phenotypic and molecular Chromatin immunoprecipitation sequencing (ChIP-Seq) characterizations on this mouse model. In our model, We used Lin- bone marrow cells as a surrogate to iden- the Asxl1 mutation was knocked in to the endogenous tify genome-wide histone modification affected by Asxl1 Asxl1 allele, thus the mice have “physiological dose” of mutations. Chromatin lysate was harvested and soni- mutation, as we see in the patients. For translating to cated with a sonicator (Bioruptor®Pico) to shear the clinical situations, we also investigated the global expres- DNA into a length ~200 bp, then it was hybridized with sion profiles of our large AML cohort to delineate the anti-H3K27me3 (Millipore, Germany). Immunoprecipi- pathophysiology related to ASXL1 mutations. We found tated DNA was sent to the National Center for Genome that bone marrow cells from Asxl1 heterozygotes formed Medicine and sequenced by Illumina HiSeq 2000 more colonies in cobblestone-area-forming assays and sequencer with 100 × 2 bp paired-end sequencing. the ability to form colonies persisted longer in serial colony-forming cell assays. On the other hand, in vivo ChIP-Seq data analysis transplantation assays showed that donor bone marrow Sequencing reads were aligned to the mm10 mouse ref- cells from Asxl1 mutant mice declined faster in their erence genome by Burrows-Wheeler Alignment tool recipients than those from the wild-type mice. While (BWA; version
Recommended publications
  • From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: the Silent Way of Cancer Progression
    biology Review From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression Carmelo Gurnari 1,2,3 , Emiliano Fabiani 1,4,* , Giulia Falconi 1 , Serena Travaglini 1 , Tiziana Ottone 1,5, Antonio Cristiano 1 and Maria Teresa Voso 1,5 1 Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy; [email protected] (C.G.); [email protected] (G.F.); [email protected] (S.T.); [email protected] (T.O.); [email protected] (A.C.); [email protected] (M.T.V.) 2 Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, 00133 Rome, Italy 3 Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA 4 Saint Camillus International, University of Health Sciences, 00131 Rome, Italy 5 Laboratorio di Neuro-Oncoematologia, Fondazione Santa Lucia, 00179 Rome, Italy * Correspondence: [email protected] Simple Summary: In the last decades the improved management of cancer patients and the overall prolonged life expectancy contributed to the increased number of patients at risk of late clonal events such as therapy-related myeloid neoplasms (t-MN). The discovery of clonal hematopoiesis of indeterminate potential (CHIP) in normal individuals has shed light on the pathophysiologic mecha- nism behind the process of myeloid evolution, defining CHIP carriers at higher risk of progression. Moreover, different patterns of clonal evolution have been identified in case of t-MN development after anti-cancer treatment exposure. The growing body of evidence in this field allowed the creation Citation: Gurnari, C.; Fabiani, E.; of dedicated cancer survivorship programs and “CHIP-Clinics” in order to specifically address the Falconi, G.; Travaglini, S.; Ottone, T.; issue of CHIP in patients undergoing anti-cancer treatment and develop measure of early detection Cristiano, A.; Voso, M.T.
    [Show full text]
  • BAP1: Case Report and Insight Into a Novel Tumor Suppressor Kanad Ghosh1, Badri Modi2, William D
    Ghosh et al. BMC Dermatology (2017) 17:13 DOI 10.1186/s12895-017-0065-6 CASEREPORT Open Access BAP1: case report and insight into a novel tumor suppressor Kanad Ghosh1, Badri Modi2, William D. James2 and Brian C. Capell1,2,3* Abstract Background: BRCA1-Associated-Protein 1 (BAP1) is a dynamic tumor suppressor which, when mutated, has been associated with an increased risk of uveal melanoma, cutaneous melanoma, mesothelioma, and several other cancers. Germline BAP1 mutations have been extensively studied, where they have been found to cause hereditary cancer susceptibility. However, their sporadic counterparts, tumors that display a loss of BAP1 expression due to somatically arising mutations in the BAP1 gene, remain a poorly described entity. Case presentation: Here we present the case of a 49-year-old female who presented with an asymptomatic dome-shaped pink papule on the dorsal foot which was found on biopsy to be deficient in the BAP1 tumor suppressor. While the patient’s family history did not suggest the presence of a familial cancer syndrome, germline genetic testing was performed and was negative. The patient underwent surgical excision of this sporadically appearing “BAPoma” by Mohs surgery. Conclusions: Given the relatively banal clinical appearance of these dome-shaped neoplasms, sporadic BAPomas may often be overlooked by clinicians and dermatologists. In addition to providing a representative case, here we also provide a synopsis of the current understanding of these neoplasms, both in terms of the histopathological features, as well as the molecular mechanisms underlying BAP1 function and its ability to prevent tumorigenesis. Keywords: BAP1, Tumor suppression, Familial cancer syndrome Background More recently, sporadic somatic BAP1 mutations have Within the last decade, the BRCA1-Associated-Protein 1 been shown to occur in the setting of both mesothelioma (BAP1) has been increasingly appreciated for its tumor sup- and uveal melanoma [3].
    [Show full text]
  • The Landscape of Somatic Mutations in Epigenetic Regulators Across 1,000 Paediatric Cancer Genomes
    ARTICLE Received 24 Sep 2013 | Accepted 12 Mar 2014 | Published 8 Apr 2014 DOI: 10.1038/ncomms4630 The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes Robert Huether1,*, Li Dong2,*, Xiang Chen1, Gang Wu1, Matthew Parker1, Lei Wei1, Jing Ma2, Michael N. Edmonson1, Erin K. Hedlund1, Michael C. Rusch1, Sheila A. Shurtleff2, Heather L. Mulder3, Kristy Boggs3, Bhavin Vadordaria3, Jinjun Cheng2, Donald Yergeau3, Guangchun Song2, Jared Becksfort1, Gordon Lemmon1, Catherine Weber2, Zhongling Cai2, Jinjun Dang2, Michael Walsh4, Amanda L. Gedman2, Zachary Faber2, John Easton3, Tanja Gruber2,4, Richard W. Kriwacki5, Janet F. Partridge6, Li Ding7,8,9, Richard K. Wilson7,8,9, Elaine R. Mardis7,8,9, Charles G. Mullighan2, Richard J. Gilbertson10, Suzanne J. Baker10, Gerard Zambetti6, David W. Ellison2, Jinghui Zhang1 & James R. Downing2 Studies of paediatric cancers have shown a high frequency of mutation across epigenetic regulators. Here we sequence 633 genes, encoding the majority of known epigenetic regulatory proteins, in over 1,000 paediatric tumours to define the landscape of somatic mutations in epigenetic regulators in paediatric cancer. Our results demonstrate a marked variation in the frequency of gene mutations across 21 different paediatric cancer subtypes, with the highest frequency of mutations detected in high-grade gliomas, T-lineage acute lymphoblastic leukaemia and medulloblastoma, and a paucity of mutations in low-grade glioma and retinoblastoma. The most frequently mutated genes are H3F3A, PHF6, ATRX, KDM6A, SMARCA4, ASXL2, CREBBP, EZH2, MLL2, USP7, ASXL1, NSD2, SETD2, SMC1A and ZMYM3. We identify novel loss-of-function mutations in the ubiquitin-specific processing protease 7 (USP7) in paediatric leukaemia, which result in decreased deubiquitination activity.
    [Show full text]
  • Genitourinary Pathology (Including Renal Tumors)
    LABORATORY INVESTIGATION THE BASIC AND TRANSLATIONAL PATHOLOGY RESEARCH JOURNAL LI VOLUME 99 | SUPPLEMENT 1 | MARCH 2019 2019 ABSTRACTS GENITOURINARY PATHOLOGY (INCLUDING RENAL TUMORS) (776-992) MARCH 16-21, 2019 PLATF OR M & 2 01 9 ABSTRACTS P OSTER PRESENTATI ONS EDUCATI ON C O M MITTEE Jason L. Hornick , C h air Ja mes R. Cook R h o n d a K. Y a nti s s, Chair, Abstract Revie w Board S ar a h M. Dr y and Assign ment Co m mittee Willi a m C. F a q ui n Laura W. La mps , Chair, C ME Subco m mittee C ar ol F. F ar v er St e v e n D. Billi n g s , Interactive Microscopy Subco m mittee Y uri F e d ori w Shree G. Shar ma , Infor matics Subco m mittee Meera R. Ha meed R aj a R. S e et h al a , Short Course Coordinator Mi c h ell e S. Hir s c h Il a n W ei nr e b , Subco m mittee for Unique Live Course Offerings Laksh mi Priya Kunju D a vi d B. K a mi n s k y ( Ex- Of ici o) A n n a M ari e M ulli g a n Aleodor ( Doru) Andea Ri s h P ai Zubair Baloch Vi nita Parkas h Olca Bast urk A nil P ar w a ni Gregory R. Bean , Pat h ol o gist-i n- Trai ni n g D e e p a P atil D a ni el J.
    [Show full text]
  • Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric
    Author Manuscript Published OnlineFirst on December 28, 2017; DOI: 10.1158/0008-5472.CAN-17-2876 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains Hongzhuang Peng1, Jeremy Prokop2, Jayashree Karar1, Kyewon Park1, Li Cao3, J. William Harbour4, Anne M. Bowcock5, S. Bruce Malkowicz6, Mitchell Cheung7, Joseph R. Testa7, and Frank J. Rauscher, 3rd1 1Wistar Institute, Philadelphia, PA, USA; 2HudsonAlpha Genome Sequencing Center, Huntsville AL, USA; 3Washington University in St Louis, St. Louis, MO; 4University of Miami School of Medicine, Miami, FL, USA; 5Icahn School of Medicine at Mount Sinai, New York, NY; 6University of Pennsylvania and Veterans Affairs Medical Center Philadelphia, Philadelphia PA, USA; 7Fox Chase Cancer Center, Philadelphia, PA, USA Running Title: BAP1 mutations disable ASXL1/2’s regulation of BAP1 activity Key Words: BAP1, PR-DUB, ASXL1/2, mutations, deubiquitinase, cancer, tumor susceptibility Correspondence: Frank J. Rauscher, 3rd, Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104; Phone: 215-898-0995; Fax: 215-898-3929; E-mail: [email protected]; Joseph R. Testa, 5Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA; Phone: 215-728- 2610; Fax: 215-214-1623; E-mail: [email protected] Précis: Combined computational and biochemical approaches demonstrate that the BAP1- ASXL2 interaction is direct and high affinity and that many BAP1 mutations act allosterically to inhibit BAP1-ASXL2 binding. 1 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 2017 American Association for Cancer Research. Author Manuscript Published OnlineFirst on December 28, 2017; DOI: 10.1158/0008-5472.CAN-17-2876 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukemia
    Letters to the Editor 1062 5 NCT00941928 http://clinicaltrials.gov. Last updated: January 6, 2010. 8 Velardi A, Ruggeri L, Moretta A, Moretta L. NK cells: a lesson from 6 Ljunggren HG, Ka¨rre K. In search of the ‘missing self’: MHC mismatched hematopoietic transplantation. Trends Immunol 2002; molecules and NK cell recognition. Immunol Today 1990; 11: 23: 438–444. 237–244. 9 Shimizu Y, Geraghty DE, Koller BH, Orr HT, DeMars R. Transfer 7 Ljunggren HG, Malmberg KJ. Prospects for the use of NK and expression of three cloned human non-HLA-A,B,C class I major cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7: histocompatibility complex genes in mutant lymphoblastoid cells. 329–339. Proc Natl Acad Sci USA 1988; 85: 227–231. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia Leukemia (2010) 24, 1062–1065; doi:10.1038/leu.2010.20; Sequences spanning exon 12 of the ASXL1 gene were amplified published online 25 February 2010 by PCR from the DNA of 300 patient samples and 111 normal controls. Primers and amplification conditions were as previously published.1 PCR products were purified and directly The identification of those genes that are frequently mutated in sequenced using the BigDye Terminator v1.1 cycle sequencing malignancies is essential for a full understanding of the molecular kit (Applied Biosystems, Foster City, CA, USA) and an ABI 3100 pathogenesis of these disorders, and often for the provision of Genetic analyzer. Sequence data were analyzed using Mutation markers for the study of disease progression.
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]
  • Prognostic Value of Chromosomal Imbalances, Gene Mutations, and BAP1
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio istituzionale della ricerca - Università di Genova Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in Uveal Melanoma. Serena Patrone1*, Irena Maric2,3*, Mariangela Rutigliani4, Francesco Lanza5, Matteo Puntoni6, Barbara Banelli7, Silvia Rancati2, Giovanna Angelini8,, Adriana Amaro8, Paolo Ligorio5, Carlotta Defferrari9, Mauro Castagnetta10, Roberto Bandelloni4, Carlo Mosci5, Andrea DeCensi9, Massimo Romani7, Urlich Pfeffer8, Silvia Viaggi2,10, §, and Domenico A. Coviello10 Department of Internal Medicine (DIMI)1, Department of Earth Sciences, Environment, and Life, Università Degli Studi di Genova, Genova (DISTAV)2, University of Genoa, Genova, Italy; Biotherapy3, Tumor Epigenetics Uni7, Molecular Pathology Unit8, Ospedale Policlinico San Martino, Genova, Italy; Pathology Unit4, Ocular Oncology Unit5, Clinical Trial Unit/Scientific Direction6, Medical Oncology Unit9, Human Genetics Laboratory10, E.O. Ospedali Galliera, Genova, Italy. died April 25, 2017 Key words: Genetic profile, BAP1 expression, uveal melanoma progression. * These authors equally contributed to the work § Corresponding author §Silvia Viaggi DISTAV University of Genoa Human Genetics Laboratory, E.O. Ospedali Galliera Via Volta, 6 I-16128 Genova [email protected] tel. 0039 0105634362 FAX 0039 010-57481384 1 ABSTRACT Uveal melanoma (UM) exhibits recurring chromosomal abnormalities and gene driver mutations, which are related to tumor evolution/progression. Almost half of the patients with UM develop distant metastases, predominantly to the liver, and so far there are no effective adjuvant therapies. An accurate UM genetic profile could assess the individual patient’s metastatic risk, and provide the basis to determine an individualized targeted therapeutic strategy for each UM patients.
    [Show full text]
  • ASXL3 Bridges BRD4 to BAP1 Complex and Governs Enhancer
    Szczepanski et al. Genome Medicine (2020) 12:63 https://doi.org/10.1186/s13073-020-00760-3 RESEARCH Open Access ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer Aileen Patricia Szczepanski1,2†, Zibo Zhao1,2†, Tori Sosnowski3, Young Ah Goo1,2,3, Elizabeth Thomas Bartom1,2 and Lu Wang1,2* Abstract Background: Small cell lung cancer (SCLC) is a more aggressive subtype of lung cancer that often results in rapid tumor growth, early metastasis, and acquired therapeutic resistance. Consequently, such phenotypical characteristics of SCLC set limitations on viable procedural options, making it difficult to develop both screenings and effective treatments. In this study, we examine a novel mechanistic insight in SCLC cells that could potentially provide a more sensitive therapeutic alternative for SCLC patients. Methods: Biochemistry studies, including size exclusion chromatography, mass spectrometry, and western blot analysis, were conducted to determine the protein-protein interaction between additional sex combs-like protein 3 (ASXL3) and bromodomain-containing protein 4 (BRD4). Genomic studies, including chromatin immunoprecipitation sequencing (ChIP-seq), RNA sequencing, and genome-wide analysis, were performed in both human and mouse SCLC cells to determine the dynamic relationship between BRD4/ASXL3/BAP1 epigenetic axis in chromatin binding and its effects on transcriptional activity. Results: We report a critical link between BAP1 complex and BRD4, which is bridged by the physical interaction between ASXL3 and BRD4 in an SCLC subtype (SCLC-A), which expresses a high level of ASCL1. We further showed that ASXL3 functions as an adaptor protein, which directly interacts with BRD4’s extra-terminal (ET) domain via a novel BRD4 binding motif (BBM), and maintains chromatin occupancy of BRD4 to active enhancers.
    [Show full text]
  • Role of the Bap1/Asxl1 Complex in Malignant Transformation and Therapeutic Response
    ROLE OF THE BAP1/ASXL1 COMPLEX IN MALIGNANT TRANSFORMATION AND THERAPEUTIC RESPONSE by Lindsay Marie LaFave A Dissertation Presented to the Faculty of the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy New York, NY July, 2015 ____________________________ ______________________ Ross L. Levine, MD Date Dissertation Mentor © 2015 Lindsay Marie LaFave DEDICATION To my parents, without your endless support and dedication none of this would have been possible. To my sister, for being the very best of friends and always making me laugh To my loving husband, for the constant happiness you bring me. You are my everything. iii ABSTRACT Role of the BAP1/ASXL1 Complex in Malignant Transformation and Therapeutic Response Somatic mutations in epigenetic modifiers have recently been identified in hematopoietic malignancies and in other human cancers. However, the mechanisms by which these epigenetic mutations lead to changes in gene expression and disease transformation have not yet been well delineated. Epigenetic modifiers include chromatin regulators that modify post-translational modifications on histone molecules. Mutations in ASXL1 (Addition of sex combs-like 1) are a common genetic event in a spectrum of myeloid malignancies and are associated with poor prognosis in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We investigated the role of ASXL1 mutations on target gene expression and chromatin state in hematopoietic cell lines and mouse models. We performed loss-of-function in vitro experiments in AML cell lines and conducted expression analysis. Loss of ASXL1 resulted in increased expression of the posterior HOXA cluster.
    [Show full text]
  • Families with BAP1-Tumor Predisposition Syndrome in the Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines
    cancers Article Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines Cindy Chau 1 , Remco van Doorn 2, Natasha M. van Poppelen 3,4, Nienke van der Stoep 5, Arjen R. Mensenkamp 6 , Rolf H. Sijmons 7, Barbara W. van Paassen 3, Ans M. W. van den Ouweland 3, Nicole C. Naus 4, Annemieke H. van der Hout 7, Thomas P. Potjer 5, Fonnet E. Bleeker 8, Marijke R. Wevers 6, Liselotte P. van Hest 9, Marjolijn C. J. Jongmans 6,10, Marina Marinkovic 1, Jaco C. Bleeker 1, Martine J. Jager 1 , Gregorius P. M. Luyten 1 and Maartje Nielsen 5,* 1 Department of Ophthalmology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands 2 Department of Dermatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands 3 Department of Clinical Genetics, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands 4 Department of Ophthalmology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands 5 Department of Clinical Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands 6 Department of Clinical Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands 7 Department of Genetics, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands 8 Department of Clinical Genetics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands 9 Department of Clinical Genetics, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands 10 Department of Clinical Genetics, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands * Correspondence: [email protected] Received: 30 June 2019; Accepted: 1 August 2019; Published: 4 August 2019 Abstract: Germline pathogenic variants in the BRCA1-associated protein-1 (BAP1) gene cause the BAP1-tumor predisposition syndrome (BAP1-TPDS, OMIM 614327).
    [Show full text]
  • The BAP1 Deubiquitinase Complex Is a General Transcriptional Co-Activator
    bioRxiv preprint doi: https://doi.org/10.1101/244152; this version posted January 8, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The BAP1 deubiquitinase complex is a general transcriptional co-activator Antoine Campagne1,2, Dina Zielinski1,2 ,3, Audrey Michaud1,2, Stéphanie Le Corre1,2, Florent Dingli1, Hong Chen1,2, Ivaylo Vassilev1,2 ,3, Ming-Kang Lee1,2, Nicolas Servant1,3, Damarys Loew1, Eric Pasmant4, Sophie Postel-Vinay5, Michel Wassef1,2* and Raphaël Margueron1,2* 1 Institut Curie, Paris Sciences et Lettres Research University, 75005 Paris, France. 2 INSERM U934/ CNRS UMR3215. 3 INSERM U900, Mines ParisTech. 4 EA7331, Faculty of Pharmacy, University of Paris Paris Descartes, Department of Molecular Genetics Pathology, Cochin Hospital, HUPC AP-HP, Paris, France. 5 Gustave Roussy, Département d'Innovation Thérapeutique et Essais Précoces, INSERM U981, Université Paris-Saclay, Villejuif, F-94805, France. *Corresponding Authors: Institut Curie - 26 rue d'Ulm, 75005 Paris Emails: [email protected] or [email protected] Tel: +33 (0)156246551 Fax: +33 (0)156246939 bioRxiv preprint doi: https://doi.org/10.1101/244152; this version posted January 8, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT In Drosophila, a complex consisting of Calypso and ASX catalyzes H2A deubiquitination and has been reported to act as part of the Polycomb machinery in transcriptional silencing. The mammalian homologs of these proteins (BAP1 and ASXL1/2/3, respectively), are frequently mutated in various cancer types, yet their precise functions remain unclear.
    [Show full text]